LFST Earnings

LFST reported its earnings on 2026-05-07, showcasing a revenue of 403.48M against an estimate of 388.20M, resulting in a 3.94% surprise. The EPS was 0.04, surpassing the expected 0.01 by 300%. The stock experienced a 20.24% price change on the earnings day and a 7.74% change over the next five days, reflecting market reactions to the results.

Following LFST's earnings announcement on 2026-05-07, the stock price moved by 20.24% on the day of the release. Over the subsequent five days, it saw a 7.74% change. Historically, LFST's stock price tends to shift by an average of -4.88% in the 10 days leading up to earnings and -1.03% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate LFST's annual revenue to reach 397.76M, while the EPS is projected at 0.01. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between LFST's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, LFST's stock price typically moves by -4.88% in the 10 days before its earnings and -1.03% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 0.01 and revenue of 397.76M.

The earnings call summary indicates positive financial performance, with strong revenue growth, improved margins, and meaningful free cash flow expected. The Q&A section reveals positive analyst sentiment, with new productivity initiatives, a strong pipeline for center openings, and a focus on leveraging AI and technology. The company also announced plans for new centers and specialty services expansion. Despite some uncertainties in clinician retention and real-time patient tracking, the overall sentiment is positive, suggesting a stock price increase of 2% to 8% over the next two weeks.